Topic 430: a new small molecule senotherapeutic for the chemoprevention of therapy-related cognitive aging
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91022C00030
- Awardee
-
Triterpenoid Therapeutics Inc. UEI JA25GYTMYJP3
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $400,000
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · PHS20221 · Posted Jul 12, 2021
- Contract value 100% obligated
- $400,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 5 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Lebanon, NH 03766, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $400,000 |
About this award
Triterpenoid Therapeutics Inc., a small disadvantaged business, was awarded a $400,000 firm fixed price Small Business Innovation Research (SBIR) Phase I contract by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The 17-month contract, set aside for total small business participation, is for research and development of "A New Small Molecule Senotherapeutic for the Chemoprevention of Therapy-Related Cognitive Aging" under Topic 430. This contract supports Triterpenoid Therapeutics' efforts to develop new medical technologies and innovative solutions aligned with NIH and Centers for Disease Control and Prevention (CDC) public health goals. Triterpenoid Therapeutics has also received prior grant funding from NCI for research related to new drug candidates targeting cancer and COVID-19 respiratory distress.
Quick answers
Who was awarded contract 75N91022C00030?
75N91022C00030 was awarded to Triterpenoid Therapeutics Inc. by National Cancer Institute (National Institutes of Health) on September 16, 2022.
How much is contract 75N91022C00030 worth?
The government has obligated $400,000 on 75N91022C00030.
Was contract 75N91022C00030 competed?
The extent of competition for 75N91022C00030 was full and open competition after exclusion of sources. The government received 5 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award